Approval for 4D Pharma to commence Phase II study in COVID-19

4D pharma, a UK-based developer of live biotherapeutics, has secured regulatory acceptance to commence a Phase II study in patients with COVID-19.

The listed pharma company will study its live biotherapeutic, MRx-4DP0004, the first immunomodulatory therapy being tested in patients hospitalised with COVID-19 which has shown the potential to simultaneously down-regulate specific pathological aspects of the hyper-inflammatory response while maintaining the appropriate anti-viral response

As MRx-4DP0004 is not broadly immunosuppressive, it does not carry the inherent side-effects associated with immunosuppressants currently under investigation, such as increased risk of infections or cancer, that may preclude their use earlier in more mild-to-moderate patients, which is crucial to reducing the burden on health systems.

MRx-4DP0004 is an orally administered, single-strain Live Biotherapeutic product (LBP) currently in a Phase I/II clinical trial for the treatment of patients with partly-controlled asthma.

4D pharma has previously shown that MRx-4DP0004 is able to significantly reduce lung inflammation and impact particular immune cell types and pathways implicated in the hyperinflammatory response to SARS-CoV-2 infection.

MRx-4DP0004 has a highly attractive safety profile with no drug-related adverse safety signals observed in preclinical studies or in patients dosed to date. As such, 4D pharma believes MRx-4DP0004 may be safely administered to patients hospitalised with COVID-19 symptoms to prevent or reduce the onset of severe inflammation.

The COVID-19 Phase II study of MRx-4DP0004 will be a randomised, double-blind, placebo-controlled trial. It will evaluate the efficacy and safety of MRx-4DP0004 in addition to standard-of-care in up to 90 patients hospitalised with symptoms indicative of COVID-19. Eligible participants will be randomised 2:1 to receive 14 days of treatment with either MRx-4DP0004 or placebo (two capsules twice daily).

Participants will be monitored daily throughout the treatment period for improvement or progression of COVID-19 symptoms and adverse events. Following completion of the treatment period, participants will be followed-up at approximately 14 and 28 days post treatment.

The primary endpoint of the trial will be the mean change in clinical status score as measured by the WHO Ordinal Scale for Clinical Improvement. Secondary endpoints include safety and tolerability as well as a suite of additional measures of clinical efficacy including the need for and duration of ventilation.

The study’s Lead Investigator is Dr Dinesh Saralaya, Consultant Respiratory Physician and Associate Director of Research at Bradford Teaching Hospitals NHS Foundation Trust, and the National Institute for Health Research’s (NIHR) Clinical Lead for Respiratory industry studies.

“As well as its appropriate mechanism of action, the highly favourable safety profile of MRx-4DP0004 makes it a particularly attractive candidate for COVID-19 patients, and may potentially allow us to prevent or delay their progression to requiring ventilation and intensive care,” she said.

A message from the Editor:

Thank you for reading this story on our news site - please take a moment to read this important message:

As you know, our aim is to bring you, the reader, an editorially led news site but journalism costs money and we rely on advertising and digital revenues to help to support them.

With the Covid-19 lockdown having a major impact on our industry as a whole, the advertising revenues we normally receive, which helps us cover the cost of our journalists and this website, have been drastically affected.

As such we need your help. If you can support our news sites with a small donation of even £1, your generosity will help us weather the storm and continue in our quest to deliver quality journalism.

In the meantime may I wish you the very best.

- Advertisement -

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...

Huadong Medicine & Exscientia to accelerate oncology drug discovery with AI

Exscientia, an AI drug discovery company, and Chinese pharma firm, Huadong Medicine, have partnered to accelerate the discovery of breakthrough small-molecule therapeutics targeted at...

Celltrion given the go-ahead for anti-COVID-19 antibody trial

Celltrion’s Investigational New Drug (IND) application for a Phase II/III pivotal clinical trial of CT-P59, an anti-COVID-19 monoclonal antibody treatment candidate, has been approved...

Related news

Study results support Owlstone Medical’s development of breath-based diagnostic tests for liver disease

Owlstone Medical, a leader in Breath Biopsy® for applications in early disease detection and precision medicine, has revealed the results of a patient study...

New partnership to take potential treatment for motor neurone disease into clinical trials

Researchers from the University of Sheffield’s Institute for Translational Neuroscience (SITraN) have been awarded a $700,000 drug development grant to progress a potential targeted...

Merck takes $1bn stake in Seattle Genetics as part of oncology collaboration

Merck is acquiring a $1 billion stake in Seattle Genetics has part of two new strategic oncology collaborations between the two companies. The companies will...

Boehringer & Click to develop digital therapeutic for schizophrenia

Boehringer Ingelheim and Click Therapeutics will together develop and commercialise of a prescription-based digital therapeutic for schizophrenia. It will utilise cognitive and neurobehavioral mechanisms delivered...